A detailed history of Citigroup Inc transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Citigroup Inc holds 724 shares of KRON stock, worth $680. This represents 0.0% of its overall portfolio holdings.

Number of Shares
724
Previous 400 81.0%
Holding current value
$680
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$0.73 - $1.38 $236 - $447
324 Added 81.0%
724 $0
Q4 2023

Feb 09, 2024

SELL
$0.75 - $1.49 $23 - $46
-31 Reduced 7.19%
400 $0
Q2 2023

Aug 10, 2023

BUY
$1.24 - $1.92 $534 - $827
431 New
431 $0
Q4 2022

Feb 09, 2023

SELL
$1.44 - $3.44 $440 - $1,052
-306 Reduced 26.15%
864 $1,000
Q3 2022

Nov 10, 2022

SELL
$3.35 - $5.55 $8,304 - $13,758
-2,479 Reduced 67.94%
1,170 $4,000
Q2 2022

Aug 10, 2022

SELL
$3.12 - $7.52 $49,062 - $118,252
-15,725 Reduced 81.17%
3,649 $13,000
Q1 2022

May 12, 2022

SELL
$6.26 - $14.42 $313,945 - $723,177
-50,151 Reduced 72.13%
19,374 $140,000
Q4 2021

Feb 10, 2022

BUY
$11.35 - $21.18 $731,836 - $1.37 Million
64,479 Added 1277.82%
69,525 $945,000
Q3 2021

Nov 10, 2021

BUY
$18.17 - $24.7 $91,685 - $124,636
5,046 New
5,046 $106,000

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $53.4M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.